메뉴 건너뛰기




Volumn 64, Issue 15, 2004, Pages 1683-1694

Telithromycin

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ATORVASTATIN; AZITHROMYCIN; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CISAPRIDE; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; KETOLIDE; MACROLIDE; METICILLIN; MEVINOLIN; MIDAZOLAM; OXACILLIN; PIMOZIDE; PRAVASTATIN; PRISTINAMYCIN; ROXITHROMYCIN; SIMVASTATIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; THEOPHYLLINE; TROVAFLOXACIN; UNINDEXED DRUG;

EID: 4344659147     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464150-00006     Document Type: Review
Times cited : (32)

References (85)
  • 1
    • 0036194907 scopus 로고    scopus 로고
    • Telithromycin: The first of the ketolides
    • Mar
    • Shain CS, Amsden GW. Telithromycin: the first of the ketolides. Ann Pharmacother 2002 Mar; 36 (3): 452-64
    • (2002) Ann Pharmacother , vol.36 , Issue.3 , pp. 452-464
    • Shain, C.S.1    Amsden, G.W.2
  • 2
    • 0035196260 scopus 로고    scopus 로고
    • Telithromycin (HMR 3647): The first ketolide antibiotic
    • Xiong Y-Q, Le TP. Telithromycin (HMR 3647): the first ketolide antibiotic. Drugs Today 2001; 37 (9): 617-28
    • (2001) Drugs Today , vol.37 , Issue.9 , pp. 617-628
    • Xiong, Y.-Q.1    Le, T.P.2
  • 3
    • 0034980950 scopus 로고    scopus 로고
    • Telithromycin
    • Barman Balfour JA, Figgitt DP. Telithromycin. Drugs 2001; 61 (6): 815-29; discussion 830-1
    • (2001) Drugs , vol.61 , Issue.6 , pp. 815-829
    • Barman Balfour, J.A.1    Figgitt, D.P.2
  • 4
    • 0035150376 scopus 로고    scopus 로고
    • Telithromycin: A new ketolide antimicrobial for treatment of respiratory tract infections
    • Feb
    • Yassin HM, Dever LL. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections. Expert Opin Investig Drugs 2001 Feb; 10 (2): 353-67
    • (2001) Expert Opin Investig Drugs , vol.10 , Issue.2 , pp. 353-367
    • Yassin, H.M.1    Dever, L.L.2
  • 6
    • 0034763651 scopus 로고    scopus 로고
    • Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site
    • Sep
    • Douthwaite S, Champney WS. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J Antimicrob Chemother 2001 Sep; 48 Suppl. T1: 1-8
    • (2001) J Antimicrob Chemother , vol.48 , Issue.SUPPL. T1 , pp. 1-8
    • Douthwaite, S.1    Champney, W.S.2
  • 7
    • 0034115717 scopus 로고    scopus 로고
    • Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA
    • Apr
    • Douthwaite S, Hansen LH, Mauvais P. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000 Apr; 36 (1): 183-93
    • (2000) Mol Microbiol , vol.36 , Issue.1 , pp. 183-193
    • Douthwaite, S.1    Hansen, L.H.2    Mauvais, P.3
  • 8
    • 0035723421 scopus 로고    scopus 로고
    • Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of gram-positive cocci
    • Jul
    • Barry AL, Fuchs PC, Brown SD. Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of gram-positive cocci. Eur J Clin Microbiol Infect Dis 2001 Jul; 20 (7): 494-7
    • (2001) Eur J Clin Microbiol Infect Dis , vol.20 , Issue.7 , pp. 494-497
    • Barry, A.L.1    Fuchs, P.C.2    Brown, S.D.3
  • 9
    • 0031942622 scopus 로고    scopus 로고
    • Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
    • Mar
    • Pankuch GA, Visalli MA, Jacobs MR, et al. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998 Mar; 42 (3): 624-30
    • (1998) Antimicrob Agents Chemother , vol.42 , Issue.3 , pp. 624-630
    • Pankuch, G.A.1    Visalli, M.A.2    Jacobs, M.R.3
  • 10
    • 0035705869 scopus 로고    scopus 로고
    • In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium
    • Verhaegen J, Verbist L. In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium. Acta Clin Belg 2001; 56 (6): 349-53
    • (2001) Acta Clin Belg , vol.56 , Issue.6 , pp. 349-353
    • Verhaegen, J.1    Verbist, L.2
  • 11
    • 0036242204 scopus 로고    scopus 로고
    • Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000
    • May
    • Low DE, de Azavedo J, Weiss K, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002 May; 46 (5): 1295-301
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.5 , pp. 1295-1301
    • Low, D.E.1    De Azavedo, J.2    Weiss, K.3
  • 12
    • 0036171320 scopus 로고    scopus 로고
    • Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci
    • Mar 3
    • Shortridge VD, Zhong P, Cao Z, et al. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob Agents Chemother 2002 Mar 3; 46: 783-6
    • (2002) Antimicrob Agents Chemother , vol.46 , pp. 783-786
    • Shortridge, V.D.1    Zhong, P.2    Cao, Z.3
  • 13
    • 0035112110 scopus 로고    scopus 로고
    • In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species
    • Mar
    • Jalava J, Kataja J, Seppälä H, et al. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob Agents Chemother 2001 Mar; 45: 789-93
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 789-793
    • Jalava, J.1    Kataja, J.2    Seppälä, H.3
  • 14
    • 0034907143 scopus 로고    scopus 로고
    • Activity of the ketolide telithromycin (HMR-3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK
    • Jul
    • Johnson AP, Henwood CJ, Tysall L, et al. Activity of the ketolide telithromycin (HMR-3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK. Int J Antimicrob Agents 2001 Jul; 18 (1): 73-6
    • (2001) Int J Antimicrob Agents , vol.18 , Issue.1 , pp. 73-76
    • Johnson, A.P.1    Henwood, C.J.2    Tysall, L.3
  • 15
    • 0036178444 scopus 로고    scopus 로고
    • In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antibiotics, including cefotaxime
    • Feb
    • Fuchs PC, Barry AL, Brown SD. In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antibiotics, including cefotaxime. J Antimicrob Chemother 2002 Feb; 49 (2): 399-401
    • (2002) J Antimicrob Chemother , vol.49 , Issue.2 , pp. 399-401
    • Fuchs, P.C.1    Barry, A.L.2    Brown, S.D.3
  • 16
    • 0034002328 scopus 로고    scopus 로고
    • Antipneumococcal activity of telithromycin by agar dilution, microdilution, e test, and disk diffusion methodologies
    • Apr
    • Davies TA, Kelly LM, Jacobs MR, et al. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies. J Clin Microbiol 2000 Apr; 38 (4): 1444-8
    • (2000) J Clin Microbiol , vol.38 , Issue.4 , pp. 1444-1448
    • Davies, T.A.1    Kelly, L.M.2    Jacobs, M.R.3
  • 17
    • 0036735145 scopus 로고    scopus 로고
    • Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin
    • Sep
    • Weiss K, Guilbault C, Cortes L, et al. Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin. J Antimicrob Chemother 2002 Sep; 50: 403-6
    • (2002) J Antimicrob Chemother , vol.50 , pp. 403-406
    • Weiss, K.1    Guilbault, C.2    Cortes, L.3
  • 18
    • 0242290103 scopus 로고    scopus 로고
    • In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis
    • Nov
    • Küçükbasmaci Ö, Gönüllü N, Aktaş Z, et al. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Int J Antimicrob Agents 2003 Nov; 22 (5): 497-501
    • (2003) Int J Antimicrob Agents , vol.22 , Issue.5 , pp. 497-501
    • Küçükbasmaci, Ö.1    Gönüllü, N.2    Aktaş, Z.3
  • 19
    • 0038440783 scopus 로고    scopus 로고
    • In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis
    • Jun
    • Goldstein EJC, Citron DM, Merriam CV, et al. In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis. Antimicrob Agents Chemother 2003 Jun; 47 (6): 1963-7
    • (2003) Antimicrob Agents Chemother , vol.47 , Issue.6 , pp. 1963-1967
    • Goldstein, E.J.C.1    Citron, D.M.2    Merriam, C.V.3
  • 20
    • 0141629339 scopus 로고    scopus 로고
    • Comparative activity of telithromycin against typical community-acquired respiratory pathogens
    • Sep
    • Buxbaum A, Forsthuber S, Graninger W, et al. Comparative activity of telithromycin against typical community-acquired respiratory pathogens. J Antimicrob Chemother 2003 Sep; 52 (3): 371-4
    • (2003) J Antimicrob Chemother , vol.52 , Issue.3 , pp. 371-374
    • Buxbaum, A.1    Forsthuber, S.2    Graninger, W.3
  • 21
    • 0036732849 scopus 로고    scopus 로고
    • Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin
    • Sep
    • Felmingham D, Reinert RR, Hirakata Y, et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002 Sep; 50 Suppl. S1: 25-37
    • (2002) J Antimicrob Chemother , vol.50 , Issue.SUPPL. S1 , pp. 25-37
    • Felmingham, D.1    Reinert, R.R.2    Hirakata, Y.3
  • 22
    • 0034956121 scopus 로고    scopus 로고
    • Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: Prevalence of mef(A) and erm(B) and susceptibilities to ketolides
    • Hoban DJ, Wierzbowski AK, Nichol K, et al. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob Agents Chemother 2001; 45 (7): 2147-50
    • (2001) Antimicrob Agents Chemother , vol.45 , Issue.7 , pp. 2147-2150
    • Hoban, D.J.1    Wierzbowski, A.K.2    Nichol, K.3
  • 23
    • 0035996126 scopus 로고    scopus 로고
    • In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Morazella catarrhalis
    • Jul
    • Schmitz FJ, Schwarz S, Milatovic D, et al. In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Morazella catarrhalis. J Antimicrob Chemother 2002 Jul; 50: 145-8
    • (2002) J Antimicrob Chemother , vol.50 , pp. 145-148
    • Schmitz, F.J.1    Schwarz, S.2    Milatovic, D.3
  • 24
    • 0034873105 scopus 로고    scopus 로고
    • In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms
    • Sep
    • Morosini M-I, Cantón R, Loza E, et al. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms. Antimicrob Agents Chemother 2001 Sep; 45: 2427-31
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 2427-2431
    • Morosini, M.-I.1    Cantón, R.2    Loza, E.3
  • 25
    • 0036146498 scopus 로고    scopus 로고
    • Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries
    • Feb
    • Nagai K, Appelbaum PC, Davies TA, et al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries. Antimicrob Agents Chemother 2002 Feb; 46 (2): 371-7
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.2 , pp. 371-377
    • Nagai, K.1    Appelbaum, P.C.2    Davies, T.A.3
  • 26
    • 0033198896 scopus 로고    scopus 로고
    • In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    • Sep
    • Hoban DJ, Zhanel GG, Karlowsky JA. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1999 Sep; 35 (1): 37-44
    • (1999) Diagn Microbiol Infect Dis , vol.35 , Issue.1 , pp. 37-44
    • Hoban, D.J.1    Zhanel, G.G.2    Karlowsky, J.A.3
  • 27
    • 0346025671 scopus 로고    scopus 로고
    • Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: Data from PROTEKT US 2000-01
    • Jan
    • Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004 Jan; 48 (1): 56-65
    • (2004) J Infect , vol.48 , Issue.1 , pp. 56-65
    • Doern, G.V.1    Brown, S.D.2
  • 28
    • 4344570402 scopus 로고    scopus 로고
    • Resistance phenotypes and multi-drug resistance among isolates of Streptococcus pneumoniae from the US during PROTEKT US Year 2 (2001-2002) [poster no. 203]. Oct 9-12; San Diego
    • Nicolau DP, Jenkins SG. Resistance phenotypes and multi-drug resistance among isolates of Streptococcus pneumoniae from the US during PROTEKT US Year 2 (2001-2002) [poster no. 203]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9-12; San Diego
    • (2003) 41st Annual Meeting of the Infectious Diseases Society of America
    • Nicolau, D.P.1    Jenkins, S.G.2
  • 29
    • 0031879816 scopus 로고    scopus 로고
    • In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae
    • Aug
    • Barry AL, Fuchs PC, Brown SD. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother 1998 Aug; 42 (8): 2138-40
    • (1998) Antimicrob Agents Chemother , vol.42 , Issue.8 , pp. 2138-2140
    • Barry, A.L.1    Fuchs, P.C.2    Brown, S.D.3
  • 30
    • 0030887438 scopus 로고    scopus 로고
    • Antimicrobial activity of RU-66647, a new ketolide
    • Jones RN, Biedenbach DJ. Antimicrobial activity of RU-66647, a new ketolide. Diagn Microbiol Infect Dis 1997; 27 (1-2): 7-12
    • (1997) Diagn Microbiol Infect Dis , vol.27 , Issue.1-2 , pp. 7-12
    • Jones, R.N.1    Biedenbach, D.J.2
  • 31
    • 0032416045 scopus 로고    scopus 로고
    • The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent
    • Dec
    • Boswell FJ, Andrews JM, Ashby JP, et al. The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent. J Antimicrob Chemother 1998 Dec; 42 (6): 703-9
    • (1998) J Antimicrob Chemother , vol.42 , Issue.6 , pp. 703-709
    • Boswell, F.J.1    Andrews, J.M.2    Ashby, J.P.3
  • 32
    • 0031780527 scopus 로고    scopus 로고
    • Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains
    • Jun
    • Biedenbach DJ, Barrett MS, Jones RN. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn Microbiol Infect Dis 1998 Jun; 31 (2): 349-53
    • (1998) Diagn Microbiol Infect Dis , vol.31 , Issue.2 , pp. 349-353
    • Biedenbach, D.J.1    Barrett, M.S.2    Jones, R.N.3
  • 33
    • 0035018240 scopus 로고    scopus 로고
    • Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae
    • Jun
    • Rospide MF, Biedenbach DJ, Jones RN. Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae. Int J Antimicrob Agents 2001 Jun; 17: 451-5
    • (2001) Int J Antimicrob Agents , vol.17 , pp. 451-455
    • Rospide, M.F.1    Biedenbach, D.J.2    Jones, R.N.3
  • 34
    • 0032852568 scopus 로고    scopus 로고
    • In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and β-haemolytic streptococci
    • Oct
    • Wootton M, Bowker KE, Janowska A, et al. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and β-haemolytic streptococci. J Antimicrob Chemother 1999 Oct; 44 (4): 445-53
    • (1999) J Antimicrob Chemother , vol.44 , Issue.4 , pp. 445-453
    • Wootton, M.1    Bowker, K.E.2    Janowska, A.3
  • 35
    • 0033055963 scopus 로고    scopus 로고
    • Ketolide treatment of Haemophilus influenzae experimental pneumonia
    • Mar
    • Piper KE, Rouse MS, Steckelberg JM, et al. Ketolide treatment of Haemophilus influenzae experimental pneumonia. Antimicrob Agents Chemother 1999 Mar; 43 (3): 708-10
    • (1999) Antimicrob Agents Chemother , vol.43 , Issue.3 , pp. 708-710
    • Piper, K.E.1    Rouse, M.S.2    Steckelberg, J.M.3
  • 36
    • 0034986363 scopus 로고    scopus 로고
    • Lung concentrations of telithromycin after oral dosing
    • Jun
    • Khair OA, Andrews JM, Honeybourne D, et al. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001 Jun; 47 (6): 837-40
    • (2001) J Antimicrob Chemother , vol.47 , Issue.6 , pp. 837-840
    • Khair, O.A.1    Andrews, J.M.2    Honeybourne, D.3
  • 37
    • 0034863518 scopus 로고    scopus 로고
    • Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones
    • Sep
    • Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001 Sep; 45: 2604-8
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 2604-2608
    • Kenny, G.E.1    Cartwright, F.D.2
  • 38
    • 0033933613 scopus 로고    scopus 로고
    • Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas
    • Jul
    • Bebear CM, Renaudin H, Bryskier A, et al. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother 2000 Jul; 44 (7): 1980-2
    • (2000) Antimicrob Agents Chemother , vol.44 , Issue.7 , pp. 1980-1982
    • Bebear, C.M.1    Renaudin, H.2    Bryskier, A.3
  • 39
    • 0034090751 scopus 로고    scopus 로고
    • In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan
    • May
    • Yamaguchi T, Hirakata Y, Izumikawa K, et al. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob Agents Chemother 2000 May; 44 (5): 1381-2
    • (2000) Antimicrob Agents Chemother , vol.44 , Issue.5 , pp. 1381-1382
    • Yamaguchi, T.1    Hirakata, Y.2    Izumikawa, K.3
  • 40
    • 0034807046 scopus 로고    scopus 로고
    • In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae
    • Miyashita N, Fukano H, Niki Y, et al. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2001; 48: 403-5
    • (2001) J Antimicrob Chemother , vol.48 , pp. 403-405
    • Miyashita, N.1    Fukano, H.2    Niki, Y.3
  • 41
    • 0031860252 scopus 로고    scopus 로고
    • In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
    • Jun
    • Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998 Jun; 42 (6): 1515-6
    • (1998) Antimicrob Agents Chemother , vol.42 , Issue.6 , pp. 1515-1516
    • Roblin, P.M.1    Hammerschlag, M.R.2
  • 42
    • 0035172060 scopus 로고    scopus 로고
    • Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens
    • Jan
    • Odenholt I, Löwdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 2001 Jan; 45 (1): 23-9
    • (2001) Antimicrob Agents Chemother , vol.45 , Issue.1 , pp. 23-29
    • Odenholt, I.1    Löwdin, E.2    Cars, O.3
  • 43
    • 0031942015 scopus 로고    scopus 로고
    • Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect
    • Feb
    • Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother 1998 Feb; 41 (2): 149-53
    • (1998) J Antimicrob Chemother , vol.41 , Issue.2 , pp. 149-153
    • Boswell, F.J.1    Andrews, J.M.2    Wise, R.3
  • 44
    • 0034117631 scopus 로고    scopus 로고
    • Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004
    • Jun
    • Munckhof WJ, Borlace G, Turnidge JD. Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004. Antimicrob Agents Chemother 2000 Jun; 44 (6): 1749-53
    • (2000) Antimicrob Agents Chemother , vol.44 , Issue.6 , pp. 1749-1753
    • Munckhof, W.J.1    Borlace, G.2    Turnidge, J.D.3
  • 45
    • 0010031083 scopus 로고    scopus 로고
    • Postantibiotic effect (PAE) and bactericidal activity of HMR 3647 and other antimicrobial agents against respiratory pathogens
    • abstract no. 1242. Sep 26-29; San Francisco
    • Dubois J, St-Pierre C. Postantibiotic effect (PAE) and bactericidal activity of HMR 3647 and other antimicrobial agents against respiratory pathogens [abstract no. 1242]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 257
    • (1999) 39th Interscience Conference on Antimicrobial Agents and Chemotherapy , pp. 257
    • Dubois, J.1    St-Pierre, C.2
  • 46
    • 0036343455 scopus 로고    scopus 로고
    • The ketolides: A critical review
    • Zhanel GG, Walters M, Noreddin A, et al. The ketolides: a critical review. Drugs 2002; 62 (12): 1771-804
    • (2002) Drugs , vol.62 , Issue.12 , pp. 1771-1804
    • Zhanel, G.G.1    Walters, M.2    Noreddin, A.3
  • 48
    • 0142026531 scopus 로고    scopus 로고
    • In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance
    • Sep
    • Ubukata K, Iwata S, Sunakawa K. In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance. J Infect Chemother 2003 Sep; 9(3): 221-6
    • (2003) J Infect Chemother , vol.9 , Issue.3 , pp. 221-226
    • Ubukata, K.1    Iwata, S.2    Sunakawa, K.3
  • 49
    • 2142819984 scopus 로고    scopus 로고
    • Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003
    • May
    • Farrell DJ, Felmingham D. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Antimicrob Agents Chemother 2004 May; 48 (5): 1882-4
    • (2004) Antimicrob Agents Chemother , vol.48 , Issue.5 , pp. 1882-1884
    • Farrell, D.J.1    Felmingham, D.2
  • 50
    • 4444257843 scopus 로고    scopus 로고
    • Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002
    • In press
    • Farrell DJ, Jenkins SG. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. J Antimicrob Chemother. In press
    • J Antimicrob Chemother
    • Farrell, D.J.1    Jenkins, S.G.2
  • 51
    • 0033958240 scopus 로고    scopus 로고
    • In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
    • Feb
    • Davies TA, Dewasse BE, Jacobs MR, et al. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000 Feb; 44 (2): 414-7
    • (2000) Antimicrob Agents Chemother , vol.44 , Issue.2 , pp. 414-417
    • Davies, T.A.1    Dewasse, B.E.2    Jacobs, M.R.3
  • 52
    • 0034605212 scopus 로고    scopus 로고
    • β-keto-ester chemistry and ketolides: Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides
    • Sep
    • Denis A, Bretin F, Fromentin C, et al. β-keto-ester chemistry and ketolides: synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. Bioorg Med Chem Lett 2000 Sep; 10 (17): 2019-22
    • (2000) Bioorg Med Chem Lett , vol.10 , Issue.17 , pp. 2019-2022
    • Denis, A.1    Bretin, F.2    Fromentin, C.3
  • 53
    • 0036911498 scopus 로고    scopus 로고
    • Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers
    • Perret C, Lenfant B, Weinling E, et al. Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy 2002; 48: 217-23
    • (2002) Chemotherapy , vol.48 , pp. 217-223
    • Perret, C.1    Lenfant, B.2    Weinling, E.3
  • 54
    • 0036970956 scopus 로고    scopus 로고
    • Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin
    • Bhargava V, Lenfant B, Perret C, et al. Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin. Scand J Infect Dis 2002; 34: 823-6
    • (2002) Scand J Infect Dis , vol.34 , pp. 823-826
    • Bhargava, V.1    Lenfant, B.2    Perret, C.3
  • 55
    • 0001394124 scopus 로고    scopus 로고
    • Effect of gastric pH on the bioavailability of telithromycin (HMR 3647)
    • abstract no. P1269
    • Lippert C, Leese PT, Sultan E. Effect of gastric pH on the bioavailability of telithromycin (HMR 3647) [abstract no. P1269]. Clin Microbiol Infect 2001; 7 Suppl. 1: 267
    • (2001) Clin Microbiol Infect , vol.7 , Issue.1 SUPPL. , pp. 267
    • Lippert, C.1    Leese, P.T.2    Sultan, E.3
  • 56
    • 0035169214 scopus 로고    scopus 로고
    • Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses
    • Jan
    • Namour F, Wessels DH, Pascual MH, et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001 Jan; 45 (1): 170-5
    • (2001) Antimicrob Agents Chemother , vol.45 , Issue.1 , pp. 170-175
    • Namour, F.1    Wessels, D.H.2    Pascual, M.H.3
  • 57
    • 0036168517 scopus 로고    scopus 로고
    • Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers
    • Mar 3
    • Kadota J-I, Ishimatsu Y, Iwashita T, et al. Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers. Antimicrob Agents Chemother 2002 Mar 3; 46 (3): 917-21
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.3 , pp. 917-921
    • Kadota, J.-I.1    Ishimatsu, Y.2    Iwashita, T.3
  • 58
    • 0034774476 scopus 로고    scopus 로고
    • Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647)
    • Nov
    • Muller-Serieys C, Soler P, Cantalloube C, et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother 2001 Nov; 45 (11): 3104-8
    • (2001) Antimicrob Agents Chemother , vol.45 , Issue.11 , pp. 3104-3108
    • Muller-Serieys, C.1    Soler, P.2    Cantalloube, C.3
  • 59
    • 1242307776 scopus 로고    scopus 로고
    • Tissue kinetics of telithromycin, the first ketolide antibacterial
    • Feb
    • Muller-Serieys C, Andrews J, Vacheron F, et al. Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother 2004 Feb; 53 (2): 149-57
    • (2004) J Antimicrob Chemother , vol.53 , Issue.2 , pp. 149-157
    • Muller-Serieys, C.1    Andrews, J.2    Vacheron, F.3
  • 60
    • 0002189635 scopus 로고    scopus 로고
    • Pharmacokinetic and clinical studies of a new ketolide antimicrobial, telithromycin (HMR 3647) in otorhinolaryngology [abstract no. 2144 plus poster]. Sep 17-20; Toronto
    • Miyamoto N, Murakami S, Yajin K, et al. Pharmacokinetic and clinical studies of a new ketolide antimicrobial, telithromycin (HMR 3647) in otorhinolaryngology [abstract no. 2144 plus poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 32
    • (2000) 40th Interscience Conference on Antimicrobial Agents and Chemotherapy , pp. 32
    • Miyamoto, N.1    Murakami, S.2    Yajin, K.3
  • 61
    • 0035992158 scopus 로고    scopus 로고
    • Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration
    • Jun
    • Namour F, Sultan E, Pascual MH, et al. Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration. J Antimicrob Chemother 2002 Jun; 49: 1035-8
    • (2002) J Antimicrob Chemother , vol.49 , pp. 1035-1038
    • Namour, F.1    Sultan, E.2    Pascual, M.H.3
  • 62
    • 0003015842 scopus 로고    scopus 로고
    • HMR 3647 achieves high and sustained concentrations in white blood cells in man
    • abstract no. P79
    • Gia HP, Roeder V, Namour F, et al. HMR 3647 achieves high and sustained concentrations in white blood cells in man [abstract no. P79]. J Antimicrob Chemother 1999; 44 Suppl. A: 57-8
    • (1999) J Antimicrob Chemother , vol.44 , Issue.SUPPL. A , pp. 57-58
    • Gia, H.P.1    Roeder, V.2    Namour, F.3
  • 63
    • 0032841480 scopus 로고    scopus 로고
    • The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells
    • Oct
    • Miossec-Bartoli C, Pilatre L, Peyron P, et al. The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells. Antimicrob Agents Chemother 1999 Oct; 43 (10): 2457-62
    • (1999) Antimicrob Agents Chemother , vol.43 , Issue.10 , pp. 2457-2462
    • Miossec-Bartoli, C.1    Pilatre, L.2    Peyron, P.3
  • 64
    • 0035016761 scopus 로고    scopus 로고
    • Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils
    • Jun
    • Mandell GL, Coleman E. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2001 Jun; 45 (6): 1794-8
    • (2001) Antimicrob Agents Chemother , vol.45 , Issue.6 , pp. 1794-1798
    • Mandell, G.L.1    Coleman, E.2
  • 65
    • 4344716387 scopus 로고    scopus 로고
    • Data on file, Aventis Pharma
    • Data on file, Aventis Pharma, 2003
    • (2003)
  • 66
    • 0003015836 scopus 로고    scopus 로고
    • Pharmacokinetic profile of HMR 3647 800 mg once-daily in elderly volunteers
    • abstract no. P66
    • Sultan E, Lenfant B, Wable C, et al. Pharmacokinetic profile of HMR 3647 800 mg once-daily in elderly volunteers [abstract no. P66]. J Antimicrob Chemother 1999; 44 Suppl. A: 54
    • (1999) J Antimicrob Chemother , vol.44 , Issue.SUPPL. A , pp. 54
    • Sultan, E.1    Lenfant, B.2    Wable, C.3
  • 67
    • 0042090159 scopus 로고    scopus 로고
    • Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment
    • Aug
    • Cantalloube C, Bhargava V, Sultan E, et al. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. Int J Antimicrob Agents 2003 Aug; 22 (2): 112-21
    • (2003) Int J Antimicrob Agents , vol.22 , Issue.2 , pp. 112-121
    • Cantalloube, C.1    Bhargava, V.2    Sultan, E.3
  • 68
    • 10744220497 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment
    • Shi J, Montay G, Chapel S, et al. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment. J Clin Pharmacol 2004; 44: 234-44
    • (2004) J Clin Pharmacol , vol.44 , pp. 234-244
    • Shi, J.1    Montay, G.2    Chapel, S.3
  • 70
    • 0002317276 scopus 로고    scopus 로고
    • HMR 3647, a new ketolide antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives
    • abstract no. 10. Sep 26-29; San Francisco
    • Scholtz HE, Sultan E, Wessels D, et al. HMR 3647, a new ketolide antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives [abstract no. 10]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 3
    • (1999) 39th Interscience Conference on Antimicrobial Agents and Chemotherapy , pp. 3
    • Scholtz, H.E.1    Sultan, E.2    Wessels, D.3
  • 71
    • 0001394124 scopus 로고    scopus 로고
    • Telithromycin (HMR 3647) does not interact with the CYP2D6 substrate paroxetine
    • abstract no. P1268
    • Lippert C, Leese PT, Sultan E. Telithromycin (HMR 3647) does not interact with the CYP2D6 substrate paroxetine [abstract no. P1268]. Clin Microbiol Infect 2001; 7 Suppl. 1: 267
    • (2001) Clin Microbiol Infect , vol.7 , Issue.1 SUPPL. , pp. 267
    • Lippert, C.1    Leese, P.T.2    Sultan, E.3
  • 72
    • 4344579563 scopus 로고    scopus 로고
    • Effects of ketoconazole and itraconazole on the pharmacokinetics of telithromycin, a new ketolide antibiotic
    • abstract no. A-1833. Sep 27-30; San Diego
    • Shi J, Montay G, Leroy B, et al. Effects of ketoconazole and itraconazole on the pharmacokinetics of telithromycin, a new ketolide antibiotic [abstract no. A-1833]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego, 28
    • (2002) 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy , pp. 28
    • Shi, J.1    Montay, G.2    Leroy, B.3
  • 73
    • 0036452858 scopus 로고    scopus 로고
    • Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia
    • Dec
    • Hagberg L, Torres A, van Rensburg D, et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002 Dec; 30 (6): 378-86
    • (2002) Infection , vol.30 , Issue.6 , pp. 378-386
    • Hagberg, L.1    Torres, A.2    Van Rensburg, D.3
  • 74
    • 1242272026 scopus 로고    scopus 로고
    • Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults
    • Dunbar LM, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004; 26(1): 48-62
    • (2004) Clin Ther , vol.26 , Issue.1 , pp. 48-62
    • Dunbar, L.M.1    Hassman, J.2    Tellier, G.3
  • 75
    • 0042689309 scopus 로고    scopus 로고
    • Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs clarithromycin (500 mg twice daily) for 10 days in the treatmentof patients with community-acquired pneumonia
    • abstract no. L-373 plus poster Sep 27-30; San Diego
    • Tellier G, Isakov T, Petermann W, et al. Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs clarithromycin (500 mg twice daily) for 10 days in the treatmentof patients with community-acquired pneumonia [abstract no. L-373 plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego, 346
    • (2002) 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy , pp. 346
    • Tellier, G.1    Isakov, T.2    Petermann, W.3
  • 76
    • 0038420015 scopus 로고    scopus 로고
    • Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults
    • Jun
    • Pullman J, Champlin J, Vrooman PS. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003 Jun; 57 (5): 377-84
    • (2003) Int J Clin Pract , vol.57 , Issue.5 , pp. 377-384
    • Pullman, J.1    Champlin, J.2    Vrooman, P.S.3
  • 77
    • 0036451201 scopus 로고    scopus 로고
    • Efficacy and safety of telithromycin in community-acquired pneumonia
    • van Rensburg DJ, Matthews PA, Bruno L. Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Med Res Opin 2002; 18 (7): 397-400
    • (2002) Curr Med Res Opin , vol.18 , Issue.7 , pp. 397-400
    • Van Rensburg, D.J.1    Matthews, P.A.2    Bruno, L.3
  • 78
    • 0002332025 scopus 로고    scopus 로고
    • Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumonlae
    • abstract no. L-857. Sep 22-25; Chicago
    • Fogarty C, Patel TC, Galbraith H, et al. Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumonlae [abstract no. L-857]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago, 449
    • (2001) 41st Interscience Conference on Antimicrobial Agents and Chemotherapy , pp. 449
    • Fogarty, C.1    Patel, T.C.2    Galbraith, H.3
  • 79
    • 0041525439 scopus 로고    scopus 로고
    • Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia
    • Jul
    • Carbon C, Moola S, Velancsics I, et al. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin Microbiol Infect 2003 Jul; 9 (7): 691-703
    • (2003) Clin Microbiol Infect , vol.9 , Issue.7 , pp. 691-703
    • Carbon, C.1    Moola, S.2    Velancsics, I.3
  • 80
    • 0036828205 scopus 로고    scopus 로고
    • Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis
    • Nov
    • Aubier M, Aldons PM, Leak A, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002 Nov; 96 (11): 862-71
    • (2002) Respir Med , vol.96 , Issue.11 , pp. 862-871
    • Aubier, M.1    Aldons, P.M.2    Leak, A.3
  • 81
    • 0037484193 scopus 로고    scopus 로고
    • Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis
    • Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res 2003; 31: 157-69
    • (2003) J Int Med Res , vol.31 , pp. 157-169
    • Zervos, M.J.1    Heyder, A.M.2    Leroy, B.3
  • 82
    • 2542424297 scopus 로고    scopus 로고
    • Comparisons of healthcare utilization in patients with acute exacerbations of chronic bronchitis (AECB) receiving telithromycin (TEL) versus clarithromycin (CLA) in a randomized, double-blind, multicenter clinical trial [abstract no. L-1595 plus poster]. Sep 14-17; Chicago
    • Mandell L, Chang J, Oster G, et al. Comparisons of healthcare utilization in patients with acute exacerbations of chronic bronchitis (AECB) receiving telithromycin (TEL) versus clarithromycin (CLA) in a randomized, double-blind, multicenter clinical trial [abstract no. L-1595 plus poster]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago, 428
    • (2003) 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy , pp. 428
    • Mandell, L.1    Chang, J.2    Oster, G.3
  • 83
    • 0036249139 scopus 로고    scopus 로고
    • Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis
    • May
    • Roos K, Brunswig-Pitschner C, Kostrica R, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 2002 May; 48 (2): 100-8
    • (2002) Chemotherapy , vol.48 , Issue.2 , pp. 100-108
    • Roos, K.1    Brunswig-Pitschner, C.2    Kostrica, R.3
  • 84
    • 0042475649 scopus 로고    scopus 로고
    • Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis
    • Aug; 586 passim
    • Luterman M, Tellier G, Lasko B, et al. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J 2003 Aug; 82 (8): 576-80, 82-4, 586 passim
    • (2003) Ear Nose Throat J , vol.82 , Issue.8 , pp. 576-580
    • Luterman, M.1    Tellier, G.2    Lasko, B.3
  • 85
    • 0242597742 scopus 로고    scopus 로고
    • A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis
    • Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol 2003; 17 (6): 369-77
    • (2003) Am J Rhinol , vol.17 , Issue.6 , pp. 369-377
    • Buchanan, P.P.1    Stephens, T.A.2    Leroy, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.